Corcept Therapeutics Incorporated (CORT)

How it makes money

All revenue comes from selling prescription tablets in the United States: patients with hypercortisolism take Korlym (or its authorized generic) chronically, and Corcept books net product revenue as those prescriptions are dispensed. There are no licensing, royalty or collaboration revenues of consequence — the income statement is essentially one line. Corcept does not sell through the usual wholesale drug channel: it uses a single specialty pharmacy that dispenses the medicine directly to patients and collects from insurers, pharmacy benefit managers, government programs and charities on the company's behalf. Optime Care filled that role from 2017 until the relationship was terminated in late 2025/early 2026, with services moved to Curant Health Georgia. Its own sales representatives and medical science liaisons call on the small number of endocrinologists who diagnose and treat the disease, so growth comes almost entirely from more patients being diagnosed and started on therapy rather than from price.

What protects Corcept is regulatory and clinical, not industrial: an approved label in a rare disease, twenty years of accumulated know-how on cortisol modulation, a patent estate around the use of mifepristone in hypercortisolism, and direct relationships with the handful of endocrinologists who manage these patients. That protection is real but visibly narrowing. A generic version of Korlym sold by Teva has competed with the company's products since January 2024, Corcept answered by launching its own authorized generic in June 2024, and on 19 February 2026 the appellate court affirmed the district court's ruling of no infringement in the patent case against Teva. The company's durable advantage now rests less on patents than on being the only firm whose entire scientific platform is cortisol modulation — and that advantage only converts into profits if the pipeline behind Korlym is approved.

Hypercortisolism is a serious chronic endocrine disease: patients do not stop treatment because the economy slows, and prescriptions do not accelerate in a boom. Demand is driven by diagnosis, not by the business cycle — how many endocrinologists recognise the condition, how many new patients are screened and started, and how long each patient stays on therapy. Corcept attributed its 2025 growth to growing recognition among physicians of the true prevalence of hypercortisolism, reporting a record number of new prescriptions and new prescribers and a materially higher number of tablets sold than in 2024. The genuine swing factors are regulatory and competitive — generic entry, payer coverage, approval or rejection of the next medicine — not GDP.

Key risks

• The whole business depends on one medicine — Corcept warns that failure to generate sufficient revenue from the sale of its Products would harm its financial results and would likely cause its stock price to decline. Operations, the research pipeline and the sales force are all funded out of Korlym revenue and existing cash; a significant decline in revenue could force the company to curtail operations or raise funds.
• Generic competition on Korlym — The company discloses that the availability of generic versions of Korlym could adversely affect its business, results of operations and financial position. Since January 2024 its products compete with a generic version of Korlym sold by Teva, and in the patent litigation the appellate court affirmed in February 2026 the lower court's finding of no infringement.
• Mifepristone is a politically exposed molecule — Corcept lists as a risk that public perception of mifepristone, or legislation limiting or barring its distribution or use for termination of early pregnancy, may limit the company's ability to sell its Products — even though its own indication is hypercortisolism, not pregnancy termination.
• Reimbursement and healthcare legislation — The filing warns that new laws, government regulations or changes to existing ones could make it difficult or impossible to obtain acceptable prices or adequate insurance coverage and reimbursement for its Products, which would adversely affect results of operations and financial position. Because almost all collections come from third-party payers, a coverage decision matters more than a commercial decision.
• A single specialty pharmacy and single-source manufacturers — Corcept identifies its reliance on one specialty pharmacy to dispense its medicines and collect payment, and its reliance on contract manufacturers to produce its products and product candidates, as risks. The concentration is concrete: Optime Care was the exclusive specialty pharmacy from 2017, was notified in June 2025 that it would lose exclusivity, received a termination notice in October 2025, and services were transferred to Curant Health Georgia between the fourth quarter of 2025 and early 2026 — a transition the company had to execute without interrupting patient supply.

The 10-K does not state a percentage of revenue attributable to the largest customers, so no number is reported here. The structure, however, is highly concentrated by design: essentially all of Corcept's medicine reaches patients through one exclusive specialty pharmacy, which also collects payment from insurers and government programs on the company's behalf — Optime Care from 2017 until its termination effective early 2026, and Curant Health Georgia thereafter. Economically the money comes from a limited set of third-party payers and pharmacy benefit managers rather than from a diversified customer base, while operationally a single vendor sits between the company and every patient.